Imidex, a Denver-based company specializing in AI for medical imaging, plans to sell its business during the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago.
The company's key asset, VisiRad XR, is an FDA-cleared AI technology designed to detect lung nodules and masses in routine chest X-rays.
"Imidex is transforming how lung cancer is detected, ensuring more patients are diagnosed at a treatable stage," said Wes Bolsen, CEO of Imidex. "We want to get the leading algorithm, cleared for detecting nodules as small as 6mm, into the hands of a company that can more rapidly deploy the solution to radiologists and healthcare providers."
VisiRad XR leverages one of the largest annotated chest X-ray data sets in the U.S., covering lung nodules and other conditions such as pneumothorax, cardiomegaly, and fractures. The data set and newly issued patents, obtained in mid-2024, bolster Imidex’s intellectual property position and are expected to offer a competitive edge to any acquiring entity.
The technology aims to address gaps in early lung cancer detection, particularly among patients who are not part of high-risk groups undergoing CT scans. According to Imidex, routine chest X-rays can help identify lung nodules as small as 6mm, offering a chance to diagnose lung cancer at earlier, more treatable stages.
The company views its technology as a "front-end patient acquisition tool," emphasizing its potential to improve outcomes by integrating with existing radiology workflows.
Imidex will be meeting with potential buyers during the RSNA meeting.
